K27/G34 versus K28/G35 in histone H3-mutant gliomas: A note of caution

  • Henning Leske
  • Elisabeth Rushing
  • Herbert Budka
  • Pitt Niehusmann
  • Jens Pahnke
  • Ioannis Panagopoulos
Correspondence

References

  1. 1.
    Bechet D, Gielen GG, Korshunov A, Pfister SM, Rousso C, Faury D, Fiset PO, Benlimane N, Lewis PW, Lu C et al (2014) Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol 128:733–741.  https://doi.org/10.1007/s00401-014-1337-4 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, Pages M, Taylor KR, Saulnier P, Lacroix L et al (2015) Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 130:815–827.  https://doi.org/10.1007/s00401-015-1478-0 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954.  https://doi.org/10.1038/nature00766 CrossRefPubMedGoogle Scholar
  4. 4.
    Iwai K, Ishikawa K, Hayashi H (1970) Amino-acid sequence of slightly lysine-rich histone. Nature 226:1056–1058CrossRefPubMedGoogle Scholar
  5. 5.
    Jansen MH, Veldhuijzen van Zanten SE, Sanchez Aliaga E, Heymans MW, Warmuth-Metz M, Hargrave D, van der Hoeven EJ, Gidding CE, de Bont ES, Eshghi OS et al (2015) Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol 17:160–166.  https://doi.org/10.1093/neuonc/nou104 CrossRefPubMedGoogle Scholar
  6. 6.
    Johnson A, Severson E, Gay L, Vergilio JA, Elvin J, Suh J, Daniel S, Covert M, Frampton GM, Hsu S et al (2017) Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist 22:1478–1490.  https://doi.org/10.1634/theoncologist.2017-0242 CrossRefPubMedGoogle Scholar
  7. 7.
    Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, Batchelor TT, Cairncross JG, van den Bent M, Wick W et al (2018) cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol.  https://doi.org/10.1007/s00401-018-1826-y Google Scholar
  8. 8.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820.  https://doi.org/10.1007/s00401-016-1545-1 CrossRefPubMedGoogle Scholar
  9. 9.
    Mohammad F, Weissmann S, Leblanc B, Pandey DP, Hojfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT et al (2017) EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med 23:483–492.  https://doi.org/10.1038/nm.4293 CrossRefPubMedGoogle Scholar
  10. 10.
    Ogino S, Gulley ML, den Dunnen JT, Wilson RB, Association for Molecular Patholpogy T, Education C (2007) Standard mutation nomenclature in molecular diagnostics: practical and educational challenges. J Mol Diagn 9:1–6.  https://doi.org/10.2353/jmoldx.2007.060081 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231.  https://doi.org/10.1038/nature10833 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University of Oslo (UiO)OsloNorway
  2. 2.Department of Pathology, Translational Neurodegeneration Research and Neuropathology LabOslo University HospitalOsloNorway
  3. 3.Institute of NeuropathologyUniversity Hospital ZurichZurichSwitzerland
  4. 4.Institute of NeurologyMedical University ViennaViennaAustria
  5. 5.Section for Cancer Cytogenetics, Institute for Cancer Genetics and InformaticsOslo University Hospital, The Norwegian Radium HospitalOsloNorway

Personalised recommendations